THE main Irish subsidiary of Allergan, the producers of Botox, last year increased its pre-tax profits by 80% to $87m (€59m).
In accounts just filed by Allergan Pharmaceuticals Holdings (Ireland) Ltd to the Companies’ Office, they show that the holding company increased its turnover by 30% from $283.5m to $369.3m to the end of December last.
The US-owned Allergan employs 840 people in Ireland with 780 people employed at its main 500,000sq ft manufacturing plant on a 30-acre campus at Westport, Co Mayo, where Botox is one of a number of pharmaceutical products made.
Allergan also employs an additional 60 people at its European and emerging markets supply chain centre based in Dublin.
Along with Botox produced at the Westport plant, Allergan also produces eyecare products at the site, while a company spokeswoman confirmed yesterday that Allergan has recently commenced production of Ozurdex, used to treat vision loss, at Westport following recent approval by the US Food and Drug Administration earlier this year.
One of Botox’s uses is the treatment of frown lines and has become widely known through its use by a number of high-profile Hollywood and media figures.
Last year, the global sales of Botox for therapeutic and cosmetic use accounted for $1.3bn of Allergan’s $4.3bn in global revenues.
The filings show that the Irish holding company’s operating profits increased last year by 129% from $26.7m to $61.4m.
© Irish Examiner Ltd. All rights reserved